Subject(s)
Antibodies, Monoclonal/adverse effects , Arthritis, Rheumatoid/drug therapy , Drug Hypersensitivity/etiology , Eosinophilia/chemically induced , Prurigo/chemically induced , Aged, 80 and over , Antibodies, Monoclonal/therapeutic use , Eosinophilia/drug therapy , Etanercept , Female , Humans , Immunoglobulin G/adverse effects , Immunoglobulin G/therapeutic use , Infliximab , Prurigo/drug therapy , Receptors, Tumor Necrosis Factor/therapeutic useABSTRACT
BACKGROUND/AIM: Extramammary Paget's disease (EMPD) is an intraepidermal adenocarcinoma of apocrine gland-bearing skin. Although surgery remains the mainstay of treatment, loss of tissue function and high recurrence rates have been reported. Recently, topical Imiquimod has been shown as a safe and effective treatment option for extramammary Paget's disease. METHODS: Three patients diagnosed of EMPD of the vulva were treated with a daily application of 5% Imiquimod cream for three weeks, followed by an every other day application for an additional three weeks. RESULTS: Complete clinical and histological remission of the disease was achieved in the three patients. Mild irritation and tenderness were observed as the only side effects. CONCLUSION: Based on our results, we consider that Imiquimod cream is a safe and effective therapeutic option for the treatment of vulvar EMPD. These promising results warrant further studies to determine the real efficacy and safety of Imiquimod 5% cream for the treatment of this uncommon disease.
Subject(s)
Aminoquinolines/administration & dosage , Antineoplastic Agents/administration & dosage , Paget Disease, Extramammary/drug therapy , Skin Neoplasms/drug therapy , Vulvar Neoplasms/drug therapy , Administration, Topical , Aged , Aged, 80 and over , Aminoquinolines/adverse effects , Antineoplastic Agents/adverse effects , Drug Administration Schedule , Female , Humans , Imiquimod , Middle Aged , Remission InductionABSTRACT
No disponible
No disponible
